Equities research analysts expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce earnings per share (EPS) of $0.56 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.43 to $0.68. Teva Pharmaceutical Industries posted earnings of $0.93 per share during the same quarter last year, which suggests a negative year over year growth rate of 39.8%. The firm is expected to announce its next earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.93 per share for the current financial year, with EPS estimates ranging from $2.80 to $3.03. For the next financial year, analysts expect that the business will report earnings of $2.80 per share, with EPS estimates ranging from $2.20 to $3.30. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. During the same quarter in the previous year, the business posted $1.00 EPS. The company’s quarterly revenue was down 19.4% on a year-over-year basis.
A number of equities analysts recently issued reports on TEVA shares. Royal Bank of Canada reiterated a “hold” rating and issued a $19.00 price target on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 31st. Wells Fargo & Co set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, August 2nd. Mizuho reiterated a “buy” rating and issued a $27.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 2nd. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 2nd. Finally, Cantor Fitzgerald set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, August 2nd. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $22.08.
In other news, VP Richard Daniell sold 2,488 shares of the stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the transaction, the vice president now directly owns 2,488 shares in the company, valued at approximately $58,940.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the transaction, the insider now owns 2,376 shares of the company’s stock, valued at $56,334.96. The disclosure for this sale can be found here. Insiders sold a total of 6,531 shares of company stock valued at $152,749 over the last 90 days. 0.43% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. CWM LLC raised its holdings in Teva Pharmaceutical Industries by 315,000.0% during the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock valued at $136,000 after buying an additional 6,300 shares during the period. Wealthstreet Investment Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $200,000. MAI Capital Management purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $204,000. FNY Investment Advisers LLC raised its holdings in Teva Pharmaceutical Industries by 989,900.0% during the 3rd quarter. FNY Investment Advisers LLC now owns 9,900 shares of the company’s stock valued at $213,000 after buying an additional 9,899 shares during the period. Finally, Greenleaf Trust purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $215,000. Institutional investors own 63.44% of the company’s stock.
Shares of TEVA stock opened at $21.86 on Tuesday. Teva Pharmaceutical Industries has a 12 month low of $13.97 and a 12 month high of $25.96. The firm has a market cap of $22.31 billion, a PE ratio of 5.56, a price-to-earnings-growth ratio of 6.62 and a beta of 0.77. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.